Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trebananib

Drug Profile

Trebananib

Alternative Names: 20060439; AMG-386

Latest Information Update: 15 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Dana-Farber Cancer Institute; Gynecologic Oncology Group; Merck Sharp & Dohme; National Cancer Institute (USA); Quantum Leap Healthcare Collaborative; Roswell Park Cancer Institute; Takeda
  • Class Antibodies; Antineoplastics; Peptides; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Angiopoietin-1 inhibitors; Angiopoietin-2 inhibitors; TIE 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Discontinued Acute myeloid leukaemia; Breast cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Glioblastoma; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 24 Jun 2018 Biomarkers information updated
  • 31 Aug 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Inoperable/Unresctable, Metastatic disease, Second-line therapy or greater) in USA (unspecified route) (NCT03239145)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top